Quantum BioPharma Sets Record Date for Litigation-Linked CVR Distribution
Quantum BioPharma has established October 27, 2025 as the record date for distributing contingent value rights that entitle shareholders to a portion of potential litigation recoveries exceeding $700 million from major financial institutions.
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has established October 27, 2025 as the record date for the distribution of contingent value rights to holders of its Class B Subordinate Voting Shares. The distribution will occur on a one-for-one basis, with each CVR entitling holders to a pro rata portion of between 10% and 50% of any net proceeds ultimately recovered from the company's ongoing litigation against CIBC World Markets, RBC Dominion Securities, and others.
The litigation seeks damages exceeding USD $700 million, representing a significant potential recovery for shareholders. The CVRs are structured as non-transferable instruments that carry no interest or voting rights. They will only become redeemable for cash if Qualifying Net Proceeds are received through either settlement or a final, non-appealable judgment in the company's favor. This structure ensures that shareholders directly benefit from any successful outcome in the legal proceedings while maintaining the company's focus on its core biopharmaceutical operations.
Quantum BioPharma's decision to issue CVRs tied to litigation outcomes represents an innovative approach to shareholder value creation in the biopharmaceutical sector. The company maintains its primary focus on developing treatments for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., Quantum BioPharma is advancing Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.
The company also maintains strategic investments through its subsidiary FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. Additional information about the company's developments and the CVR distribution can be found in the full press release available at https://ibn.fm/P9Wrt. Investors seeking ongoing updates about Quantum BioPharma can access the company's newsroom at https://ibn.fm/QNTM.